Department of Orthopaedics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Am J Sports Med. 2011 Aug;39(8):1623-9. doi: 10.1177/0363546511404877. Epub 2011 May 21.
Achilles tendinopathy is a common disease among both athletes and in the general population in which the use of platelet-rich plasma has recently been increasing. Good evidence for the use of this autologous product in tendinopathy is limited, and data on longer-term results are lacking.
To study the effects of a platelet-rich plasma injection in patients with chronic midportion Achilles tendinopathy at 1-year follow-up.
Randomized controlled trial; Level of evidence, 1.
Fifty-four patients, aged 18 to 70 years, with chronic tendinopathy 2 to 7 cm proximal to the Achilles tendon insertion were randomized to receive either a blinded injection containing platelet-rich plasma or saline (placebo group) in addition to an eccentric training program. The main outcome was the validated Victorian Institute of Sports Assessment-Achilles score. Patient satisfaction was recorded and ultrasound examination performed at baseline and follow-up.
The mean Victorian Institute of Sports Assessment-Achilles score improved in both the platelet-rich plasma group and the placebo group after 1 year. There was no significant difference in increase between both groups (adjusted between-group difference, 5.5; 95% confidence interval, -4.9 to 15.8, P = .292). In both groups, 59% of the patients were satisfied with the received treatment. Ultrasonographic tendon structure improved significantly in both groups but was not significantly different between groups (adjusted between-group difference, 1.2%; 95% confidence interval, -4.1 to 6.6, P = .647).
This randomized controlled trial showed no clinical and ultrasonographic superiority of platelet-rich plasma injection over a placebo injection in chronic Achilles tendinopathy at 1 year combined with an eccentric training program.
跟腱病是运动员和普通人群中常见的疾病，最近富血小板血浆的应用有所增加。这种自体产品在跟腱病中的应用的证据有限，并且缺乏长期结果的数据。
研究富血小板血浆注射治疗慢性中段跟腱病患者的 1 年随访结果。
随机对照试验；证据水平，1 级。
54 例年龄 18 至 70 岁的慢性跟腱病患者，跟腱附着处近端 2 至 7 厘米处，随机分为富血小板血浆组或生理盐水（安慰剂组）联合离心训练方案进行盲注。主要结局指标是经过验证的维多利亚运动评估-跟腱评分。记录患者满意度，并在基线和随访时进行超声检查。
富血小板血浆组和安慰剂组在 1 年后的维多利亚运动评估-跟腱评分均有改善。两组之间的增加没有显著差异（调整后的组间差异为 5.5；95%置信区间为-4.9 至 15.8，P=.292）。两组中，59%的患者对接受的治疗满意。两组的超声肌腱结构均有显著改善，但组间无显著差异（调整后的组间差异为 1.2%；95%置信区间为-4.1 至 6.6，P=.647）。
这项随机对照试验显示，在慢性跟腱病中，富血小板血浆注射联合离心训练方案在 1 年时与安慰剂注射相比，在临床和超声方面均无优势。
